Shares of Novavax Inc. NVAX shed 2.94% to $6.94 Friday, on what proved to be an all-around dismal trading session for the ...

Explore why Novavax, Inc. faces profitability challenges despite a promising tech platform, with uncertain revenue streams.

Novavax's COVID-19-influenza vaccines show strong immune response in older adults, paving the way for regulatory approval.

The RSV shot, mRESVIA, secured U.S. approval on Thursday for expanded use in at-risk adults aged 18 to 59 years, but needs ...

FDA drug alerts in infectious diseases, including new drug approvals, safety warnings, recalls, and changes in indications.

The Department of Health and Human Services has defended cuts to vaccine research with statements that mislead on the safety ...

The agency’s decision to clear Moderna’s shot for use in certain younger adults is a much-needed win for a company that’s ...

The data showed that both the CIC and flu vaccine candidates induced immune responses similar to licensed comparators ...